Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
Recruiting
Phase 1
Interventional Study
Infertility
Obesity
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 19 – 37
- Sex
- Female
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 5 (estimated)
- Sponsor
- University of Colorado, Denver · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Hypothesis: The investigators hypothesize that pulsatile FSH intravenous administration to women with obesity will correct the Reprometabolic Syndrome (RMS) luteal deficiency phenotype.
Specific Aim: To test the hypothesis that pulsatile IV administration of FSH will rescue the impaired folliculogenesis and relative hypogonadotropic hypogonadism, characteristic of obesity. The investigators will …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* • BMI between 30 kg/m2 and 40 kg/m
* Weight stability, i.e. no continued weight loss of \>1lb per week for a minimum of 4 weeks prior to enrollment
* Normal thyroid stimulating hormone (TSH) and prolactin
* Anti-Mullerian Hormone (AMH) \> 1 ng/ml or \< 8 ng/mL
* Willi…
Contacts